Dickinson Klara 4

Accession 0000950170-24-035458

CIK 0001042074other

Filed

Mar 21, 8:00 PM ET

Accepted

Mar 22, 5:02 PM ET

Size

22.4 KB

Accession

0000950170-24-035458

Form 4

Period: 2024-03-22

SVP, Regulatory Affairs & QA

Transactions

Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−215,000→ 0 total
Exercise: $7.80Exp: 2033-01-24→ Common Stock (215,000 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−328,299→ 0 total
Exercise: $4.05Exp: 2030-05-14→ Common Stock (328,299 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−78,000→ 0 total
Exercise: $22.85Exp: 2034-01-23→ Common Stock (78,000 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−200,000→ 0 total
Exercise: $5.50Exp: 2027-06-27→ Common Stock (200,000 underlying)
Disposition to Issuer
Common Stock
2024-03-22−21,000→ 0 total
Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−100,000→ 0 total
Exercise: $11.69Exp: 2028-01-23→ Common Stock (100,000 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−138,312→ 0 total
Exercise: $8.43Exp: 2029-01-28→ Common Stock (138,312 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−66,500→ 0 total
Exercise: $5.78Exp: 2031-01-25→ Common Stock (66,500 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−175,000→ 0 total
Exercise: $2.94Exp: 2032-01-24→ Common Stock (175,000 underlying)

Footnotes (2)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay restricted stock unit award was cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of CymaBay common stock subject to such restricted stock unit award and (ii) $32.50, less applicable withholding taxes.
[F2]Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Documents

1 file

CymaBay Therapeutics, Inc.

CIK 0001042074

Entity typeother